Pillar Biosciences Incorporated, founded in 2014 by Dr. Gang Song and Dr. Zhaohui Wang, received its Series A funding of $18M in May of 2016[1] from Hong Kong-based ORI Healthcare[2] and is headquartered in Natick Massachusetts.
Pillar Biosciences signed an in-vitro diagnostics partnership with DNA sequencing provider Illumina Incorporated in October of 2017[3], and has received ISO 13485:2016 certification for design, development, manufacture and distribution of products for the clinical diagnostics laboratory.[4]
Pillar Biosciences' focus is to develop and manufacture targeted next-generation sequencing (NGS)-based assays and software for high-throughput speciality NGS laboratories, and is beginning to commercialize kits and software for the translational research market.
References[edit]
- ↑ "Cancer Dx Firm Pillar Biosciences Gets $18M Investment From ORI Healthcare". GenomeWeb. Retrieved 2018-06-01.
- ↑ "ORI Healthcare Fund Invests in Pillar Biosciences". Retrieved 2018-06-01.
- ↑ "Illumina and Pillar Biosciences, Inc. Announce Agreement". www.illumina.com. Retrieved 2018-06-01.
- ↑ Inc., Pillar Biosciences,. "Pillar Biosciences announces ISO 13485:2016 Certification". www.prnewswire.com. Retrieved 2018-06-01.
This article "Pillar Biosciences" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Pillar Biosciences. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.